X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxto
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
The study demonstrates that for patients receiving melphalan flufenamide, also known as melflufen and dexamethasone in the phase 2 BRIDGE study, the exposure to melphalan increased with reduced eGFR similar to what is observed during treatment with melphalan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
RhoVac reported that as Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination causing a delay in RhoVac's Phase IIb study.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
